NDRA · ENDRA Life Sciences Inc.

Summary

ENDRA Life Sciences Inc. initiated a process to evaluate strategic alternatives, including mergers, asset sales, or business combinations, to maximize shareholder value, and engaged Lucid Capital Management and K&L Gates. On March 19, 2026, it reduced employees, expecting approximately $51,000 in pre-tax cash severance charges in Q1 2026 to extend its operational runway.

Key takeaways

• Initiated strategic alternatives review on March 25, 2026, including potential mergers, investments, or sale of the Company
• Reduced number of employees on March 19, 2026, to reduce cash expenditures
• Expects $51,000 pre-tax cash charges for severance payments to former employees in Q1 2026
• Engaged Lucid Capital Management as financial advisor and K&L Gates as legal counsel
• Will continue to pursue TAEUS business during the review process
• No timetable set for completion of the strategic review process